The b-amyloid (Ab) peptide, the likely cause of Alzheimer's disease (AD), is derived from the sequential cleavage of amyloid precursor protein (APP) by two enzymes, the b-and g-secretases.
The b-secretase, identified as the novel transmembrane aspartic protease b-site APP-cleaving enzyme (BACE), initiates the production of Ab (Vassar, 2005) . Thus, BACE is a promising therapeutic target, since BACE inhibitor drugs may reduce Ab formation and alleviate AD. Conversely, conditions that increase BACE activity are predicted to be amyloidogenic and may exacerbate AD. Recent reports show that levels of BACE protein and activity are increased in AD brain (Fukumoto et al., 2002; Holsinger et al., 2002; Li et al., 2004; Yang et al., 2003) . Moreover, BACE levels rise following physiological stress or injury, such as oxidative stress (Tamagno et al., 2002) , traumatic brain injury (Blasko et al., 2004) , ischemia (Wen et al., 2004) , hypoxia (Zhang et al., 2007) , and energy inhibition (Velliquette et al., 2005) . These results imply that age-related stress may increase BACE levels and drive AD pathogenesis.
In this issue of Neuron, Tesco and colleagues (Tesco et al., 2007) report a posttranslational mechanism of BACE stabilization that provides insight into what may give rise to the BACE increase in AD. Interestingly, apoptosis and caspase activation are involved, processes that have been linked to AD. In their previous work, the authors showed that apoptosis elevates Ab production in cells (Tesco et al., 2003) . Moreover, this effect was independent of caspase cleavage of APP and therefore may have been due to increased b-secretase activity. These results suggested that apoptosis might enhance BACE processing of APP. In the present report, Tesco and colleagues tested this hypothesis first by showing that apoptosis increases BACE levels several fold in neural and nonneural cells. Levels of C99, the C-terminal APP fragment that is the precursor of Ab, were also elevated, caspase-3 was activated, and all effects were blocked by the caspase inhibitor zVAD. Interestingly, the rise in BACE level was not the result of increased BACE mRNA level, suggesting a posttranscriptional mechanism. Indeed, pulse-chase and cycloheximide experiments showed that apoptosis increases the protein half-life of BACE. These results demonstrate that apoptosis stabilizes BACE, thus causing elevated b-secretase activity.
Next, to determine the cause of the BACE stabilization, the researchers drew upon their earlier work showing that BACE is degraded in the lysosome, a process that depends on a dileucine motif in the cytosolic tail of BACE (Koh et al., 2005) . Dileucine motifs bind Golgi-localized g-earcontaining ARF-binding proteins (GGAs), a family of adaptors that function in intracellular sorting (Bonifacino, 2004) . Since lysosomal degradation of the epidermal growth factor receptor (EGFR) requires GGA3, Tesco et al.
hypothesized that GGA3 is responsible for BACE trafficking to the lysosome. They also reasoned that caspase cleavage of GGA3 during apoptosis might result in GGA3 deficiency causing the accumulation of BACE in endosomes where Ab is generated. Indeed, GGA3 was cleaved into several fragments during apoptosis in cells and by recombinant caspase-3 in cell-free assays, effects that were blocked by zVAD. Importantly, the observed GGA3 fragment sizes matched the predicted sizes based on four putative caspase cleavage sites in the hinge domain of GGA3. Site-directed mutagenesis of critical aspartic acids in these sites abolished GGA3 fragmentation during apoptosis in cells and by recombinant caspase-3 in vitro. Intriguingly, an N-terminal GGA3 fragment that mimics caspase cleavage at position 313 acted like a dominant negative (DN) and caused BACE levels to rise in transfected cells. These results indicate that caspase cleavage of GGA3 may both reduce levels of the adaptor and create a DN molecule, thus additively stabilizing BACE. To conclude this thorough set of mechanistic experiments, the authors used RNA interference (RNAi) to knock down GGA3 levels in neural and nonneural cells and showed that GGA3 RNAi elevates levels of BACE, C99, and Ab. The fact that DN GGA3 and GGA3 RNAi both caused BACE elevation is strong evidence that caspase cleavage of GGA3 underlies the BACE stabilization during apoptosis.
To show that caspase cleavage of GGA3 is relevant to apoptosisinduced BACE stabilization in vivo, Tesco et al. next used a rat model of cerebral ischemia. Indeed, ischemia increased BACE levels and caspase activation. At the same time, full-length GGA3 was reduced while caspasecleaved GGA3 appeared. Finally, to show relevance to AD, the authors demonstrated that GGA3 levels are reduced in AD brain and that an inverse correlation exists between BACE and GGA3 levels. No such correlation was found in nondemented (ND) brain. Although activated caspase-3 fragment was not observed in AD brain, decreased full-length caspase-3 suggested caspase activation. Interestingly, GGA3 levels in AD cerebellum, a brain region typically lacking AD pathology, were not as reduced as in AD temporal cortex. BACE levels in AD cerebellum were similar to those in ND, suggesting that cerebellar GGA3 levels are sufficient for BACE lysosomal degradation. These results imply the corollary that individuals with lower levels of GGA3, especially in AD-susceptible brain regions, may be at greater risk for developing AD.
The results of Tesco et al. suggest a model of BACE stabilization in which GGA3 normally targets BACE to the lysosome for degradation, keeping BACE levels and Ab generation low ( Figure 1A) . However, during apoptosis, GGA3 is cleaved by caspase-3, thus reducing GGA3 levels and creating DN GGA3 ( Figure 1B) . As a result, BACE lysosomal degradation is reduced, allowing BACE to accumulate in endosomes and drive Ab production.
Several key questions arise from this important study. First, characterization of the compartment in which BACE accumulates would help understand both BACE trafficking and Ab formation. Further in vivo studies of the amyloidogenic effects of BACE stabilization, perhaps by depleting GGA3 with GGA3 RNAi, would be informative, especially in AD mouse models such as APP transgenic mice. In addition, it will be important to determine whether caspase-3 inhibition or GGA3 overexpression ameliorates amyloid pathology in APP transgenics. This work provides a rationale for the search of GGA3 gene mutations in AD that reduce GGA3 function by lowering expression, stability, or BACE binding. Alternatively, mutations that promote DN GGA3 formation may also be associated with AD. Determining whether there may be a function to BACE stabilization would be of considerable interest. Growing evidence suggests that BACE is a stress-response enzyme, although it is unclear what protective function BACE elevation might provide during stress, if any. Finally, other mechanisms besides BACE stabilization may cause BACE elevation. For example, transcriptional activation of the BACE gene occurs under hypoxia via the transcription factor hypoxiainducing factor 1 (HIF1; Zhang et al., 2007) . Studies also suggest that BACE translation may be regulated (Lammich et al., 2004) . Future investigation will be required to determine the extent to which these or other mechanisms may contribute to the BACE elevation in AD.
Stroke and cerebrovascular disease are possible risk factors for AD, and together with the results of Tesco et al., suggest that ischemia-induced caspase activation followed by GGA3 depletion may be a precipitating event in AD. Alternatively, cumulative agerelated insults to the brain may achieve similar results, thus starting a vicious cycle of BACE elevation and Ab generation. In conclusion, the work of Tesco and colleagues provides critical insight into a potentially important mechanism of BACE elevation in AD. (1) from the trans-golgi network (TGN) to the plasma membrane (PM) and undergoes endocytosis (2a) into endosomes (E), or BACE can directly traffic to endosomes (2b). In the endosome, BACE cleaves APP (not shown) and initiates Ab formation. GGA3 binds to the cytosolic tail of BACE and targets the enzyme (3) to the lysosome (L) for degradation. Caspase-3 is inactive under normal conditions. (B) During apoptosis, caspase-3 is activated and cleaves GGA3 in the hinge domain, thus reducing full-length GGA3 levels and creating a dominantnegative molecule. As a result, BACE sorting to the lysosome is reduced, thereby stabilizing BACE in the endosome where it accumulates and elevates Ab generation.
We are still far from reaching a complete understanding of the molecular mechanisms that control neuronal diversification during nervous system development. In this issue of Neuron, Luo et al. bring that goal a step closer by revealing how a hierarchical interaction between two neurotrophic factor systems drives the differentiation, maturation, and extension of peripheral projections in a subclass of sensory neurons that mediate pain perception.
The molecular mechanisms responsible for the specification of distinct sensory modalities are being intensely investigated, not only because of the obvious clinical importance of pain control, but also as a powerful model system of neuronal diversification. Pain perception following harmful mechanical, thermal, and chemical stimuli is mediated by the activation of paintransducing-i.e., nociceptive-sensory neurons in the dorsal root ganglia (DRG). Nociceptive, mechanoceptive, and proprioceptive sensory neuron subtypes emerge from migratory neural crest cells shortly after neural tube closure and continue to diversify by acquiring distinct functional characteristics long after birth (Hjerling-Leffler et al., 2007) . Nociceptors express a diverse collection of ion channels that allow them to transduce external stimuli into electrical activity. The generation of nociceptor cell diversity is believed to be controlled by hierarchical interactions between cell intrinsic and extrinsic signals (Marmigere and Ernfors, 2007) . All nociceptive neurons initially express the transcription factor Runx1 and the nerve growth factor (NGF) receptor TrkA, which mediates target-dependent cell survival during the period of programmed cell death. Around birth, and during the first 2 to 3 postnatal weeks, a fraction of nociceptive neurons switch their neurotrophic factor dependence by downregulating expression of TrkA and upregulating that of Ret, a signaling subunit of the receptor complex for members of the GDNF (glial cell linederived neurotrophic factor) ligand family. TrkA + and Ret + nociceptors are also distinguished by the presence or absence of the neuropeptides calcitonin gene-related peptide (CGRP) and substance P (SP)-hence classified as peptidergic or nonpeptidergic subtypes-and believed to mediate inflammatory or neuropathic pain, respectively. While developing nonpeptidergic nociceptors lose TrkA, maintain Runx1, and gain Ret expression, peptidergic sensory neurons retain TrkA but lose Runx1 as they mature (Chen et al., 2006) . The contribution of NGF/TrkA signaling to sensory neuron diversification and maturation has been studied in mice lacking the proapoptotic molecule Bax, a mutation that bypasses the early developmental requirement of neurotrophic support for cell survival.
